SCHEMBL407111

SCHEMBL407111

Cc1ccc(NCC(O)Cn2c3ccc(Cl)cc3c3cc(Cl)ccc32)cc1

nearest known ligand 0.60

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
DNM1 Q05193 7/20 0.55
RAD52 P43351 1/20 0.51
NLRP1 Q9C000 1/20 0.51
ALDH1A1 P00352 3/20 0.51
LMNA P02545 2/20 0.51
MAPT P10636 2/20 0.46
KMT2A Q03164 2/20 0.46
MEN1 O00255 1/20 0.46
GAA P10253 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
USP2 O75604 1/20 0.46
HSP90AA1 P07900 1/20 0.46
MAPK1 P28482 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
RCE1 Q9Y256 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28594492 0.92 DNM1 (0.60) DNM1RAD52NLRP1ALDH1A1LMNA
SCHEMBL410748 0.87 DNM1 (0.69) DNM1RAD52NLRP1ALDH1A1MAPT
SCHEMBL410011 0.87 DNM1 (0.72) DNM1RAD52NLRP1ALDH1A1LMNA
SCHEMBL28581789 0.86 MAPT (0.60) DNM1RAD52NLRP1ALDH1A1LMNA
SCHEMBL18925966 0.85 DNM1 (0.73) DNM1RAD52NLRP1ALDH1A1LMNA
SCHEMBL410581 0.85 DNM1 (0.77) DNM1RAD52ALDH1A1LMNAMAPT
SCHEMBL408405 0.82 DNM1 (0.77) DNM1RAD52ALDH1A1LMNAMAPT
SCHEMBL409461 0.81 DNM1 (0.78) DNM1ALDH1A1LMNAMAPTKMT2A
SCHEMBL21093179 0.80 RAD52 (0.54) DNM1RAD52NLRP1ALDH1A1LMNA
SCHEMBL16923756 0.80 DNM1 (0.55) DNM1ALDH1A1LMNAMAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 170 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180318255-A1 Pro-Neurogenic Compounds BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2018-11-08 US claimed
EP-2590647-B1 PRO-NEUROGENIC COMPOUNDS UNIV TEXAS (US) 2017-11-08 EP claimed
US-20170157092-A1 Anti-depression Compounds BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2017-06-08 US claimed
US-20160362372-A1 PRO-NEUROGENIC COMPOUNDS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2016-12-15 US claimed
US-20160206596-A1 Anti-depression Compounds BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2016-07-21 US claimed
US-20160206594-A1 Pro-Neurogenic Compounds NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-07-21 US claimed
US-20150290195-A1 PRO-NEUROGENIC COMPOUNDS BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2015-10-15 US claimed
EP-2925129-A1 PRO-NEUROGENIC COMPOUNDS Board of Regents of the University of Texas System (US) 2015-10-07 EP claimed
US-20150057301-A1 Pro-Neurogenic Compounds NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-02-26 US claimed
US-20140343018-A1 Anti-depression Compounds NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2014-11-20 US claimed
US-20130184301-A1 Methods of Treating Post-Traumatic Stress Disorder Using Pro-Neurogenic Compounds BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2013-07-18 US claimed
EP-2590647-A2 PRO-NEUROGENIC COMPOUNDS Board of Regents of the University of Texas System (US) 2013-05-15 EP claimed
US-20130040977-A1 Pro-Neurogenic Compounds BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2013-02-14 US claimed
US-20120022096-A1 PRO-NEUROGENIC COMPOUNDS BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2012-01-26 US claimed
WO-2012006419-A2 PRO-NEUROGENIC COMPOUNDS BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2012-01-12 WO claimed
EP-2385829-A1 PRO-NEUROGENIC COMPOUNDS Board of Regents of the University of Texas System (US) 2011-11-16 EP claimed
US-8039041-B2 Electroluminescent devices with electrode protection CAMBRIDGE DISPLAY TECHNOLOGY, LTD. (GB) 2011-10-18 US claimed
US-20110015217-A1 Pro-Neurogenic Compounds BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2011-01-20 US claimed
US-20110003836-A1 Pro-Neurogenic Compounds BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2011-01-06 US claimed
WO-2010081115-A1 PRO-NEUROGENIC COMPOUNDS UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER (US) 2010-07-15 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130184301-A1 Methods of Treating Post-Traumatic Stress Disorder Using Pro-Neurogenic Compounds BDNF, GAP43, DCX DNM1 1086/4885RAD52 4328/4885NLRP1 4743/4885
US-20120022096-A1 PRO-NEUROGENIC COMPOUNDS BDNF, GAP43, DCX DNM1 897/4885RAD52 3297/4885NLRP1 4848/4885
US-20160206594-A1 Pro-Neurogenic Compounds DCX, GAP43, BDNF DNM1 510/4885RAD52 4273/4885NLRP1 4107/4885
US-20150057301-A1 Pro-Neurogenic Compounds DCX, GAP43, BDNF DNM1 625/4885RAD52 4362/4885NLRP1 3786/4885
US-20180318255-A1 Pro-Neurogenic Compounds BDNF, GAP43, DCX DNM1 897/4885RAD52 3297/4885NLRP1 4848/4885
US-20110015217-A1 Pro-Neurogenic Compounds DCX, GAP43, BDNF DNM1 510/4885RAD52 4273/4885NLRP1 4107/4885
US-20150290195-A1 PRO-NEUROGENIC COMPOUNDS DCX, GAP43, BDNF DNM1 510/4885RAD52 4273/4885NLRP1 4107/4885
US-20140343018-A1 Anti-depression Compounds BDNF, DCX, GAP43 DNM1 638/4885RAD52 2718/4885NLRP1 4852/4885
US-20130040977-A1 Pro-Neurogenic Compounds BDNF, GAP43, DCX DNM1 897/4885RAD52 3297/4885NLRP1 4848/4885
US-20110003836-A1 Pro-Neurogenic Compounds DCX, GAP43, BDNF DNM1 538/4885RAD52 4298/4885NLRP1 4099/4885
US-20160362372-A1 PRO-NEUROGENIC COMPOUNDS DCX, GAP43, BDNF DNM1 510/4885RAD52 4273/4885NLRP1 4107/4885
US-20160206596-A1 Anti-depression Compounds BDNF, DCX, GAP43 DNM1 638/4885RAD52 2718/4885NLRP1 4852/4885
US-20170157092-A1 Anti-depression Compounds BDNF, DCX, GAP43 DNM1 638/4885RAD52 2718/4885NLRP1 4852/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.